MedTrace Logo

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

NCT04342117 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2021-03-17

No results posted yet for this study

Summary

This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.

Conditions

Interventions

DRUG

duvelisib

25 mg BID, 15 mg BID

DRUG

PI3K inhibitor

FDA approved PI3K inhibitors

Sponsors & Collaborators

  • SecuraBio

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-23
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04342117 on ClinicalTrials.gov